Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1216 participants.
Also called NCT03539445
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,216 participants
- Sponsor
- Registry
-
NCT03539445
-
- Other papers using this trial's data
- Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial
- Favorable Systemic Immune-Inflammation Status Enhances the Neuroprotective Effects of Butylphthalide in Ischemic Stroke: A Post Hoc Analysis of BAST Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03539445. Randomized; quadruple masking; primary purpose treatment. Start 2018-07-01 (actual); primary completion 2022-05-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment
- Acronym
- BAST
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Butylphthalide
- Intervention (Drug)
- Butylphthalide Placebo
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct03539445- Content hash
31e306f7d14b8d28400077bad01da767413aeece4097b630916a509be7862d7a